Envista (NYSE:NVST) Releases FY 2026 Earnings Guidance

Envista (NYSE:NVST) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.350-1.450 for the period, compared to the consensus earnings per share estimate of 1.270. The company issued revenue guidance of -.

Envista Stock Up 4.8%

Envista stock traded up $1.15 during trading hours on Thursday, reaching $24.81. The stock had a trading volume of 9,440,264 shares, compared to its average volume of 2,937,165. The company has a market cap of $4.08 billion, a price-to-earnings ratio of 275.66, a PEG ratio of 1.02 and a beta of 1.01. The business’s 50 day moving average price is $22.56 and its 200-day moving average price is $21.14. Envista has a 52 week low of $14.22 and a 52 week high of $25.41. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.37 and a quick ratio of 2.02.

Envista (NYSE:NVST) last issued its quarterly earnings data on Thursday, February 5th. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.32 by $0.06. Envista had a net margin of 0.58% and a return on equity of 5.90%. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. Sell-side analysts anticipate that Envista will post 1 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Stifel Nicolaus upped their price target on Envista from $25.00 to $27.00 and gave the stock a “buy” rating in a research report on Wednesday. Robert W. Baird set a $27.00 target price on Envista in a research report on Friday, October 31st. Evercore ISI reissued an “outperform” rating on shares of Envista in a report on Friday, October 31st. Mizuho set a $24.00 price target on Envista and gave the stock a “neutral” rating in a research note on Tuesday, January 20th. Finally, Piper Sandler increased their price objective on shares of Envista from $19.00 to $21.00 and gave the company a “neutral” rating in a research report on Friday, January 30th. Five investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $22.75.

Institutional Investors Weigh In On Envista

Several hedge funds have recently modified their holdings of NVST. Caitong International Asset Management Co. Ltd increased its stake in shares of Envista by 16,711.1% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock valued at $31,000 after purchasing an additional 1,504 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Envista by 73.1% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock valued at $44,000 after buying an additional 949 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Envista by 378.0% in the second quarter. EverSource Wealth Advisors LLC now owns 2,414 shares of the company’s stock valued at $47,000 after buying an additional 1,909 shares in the last quarter. Quarry LP acquired a new position in shares of Envista during the 3rd quarter worth approximately $66,000. Finally, Virtus Advisers LLC purchased a new position in shares of Envista during the 3rd quarter valued at approximately $205,000.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.